Investigating Dichloroacetate for treating aggressive brain tumors
Official title: Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019
Funded at University of Florida · NIH-10919168 · Data updated 2026-11-12
This study is looking at how well a treatment called dichloroacetate (DCA) works for people with glioblastoma, a tough type of brain tumor, to see if it can help improve their health and survival.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $669,027 |
| NIH project number | 5R01FD007271-04 |
| Project ID | NIH-10919168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma multiforme who have undergone standard treatment but are facing tumor recurrence.
✕Less likely to help
Patients with other types of brain tumors or those who have not been diagnosed with glioblastoma multiforme may not benefit from this research.
What this research studies
This research focuses on glioblastoma multiforme (GBM), a highly aggressive brain tumor with limited treatment options. The study aims to evaluate the effectiveness of dichloroacetate (DCA), a compound that can inhibit certain enzymes involved in tumor metabolism, potentially improving patient outcomes. By targeting the metabolic processes of GBM, the research seeks to provide a new therapeutic approach that could enhance survival rates. Patients will be monitored for safety and efficacy as they receive DCA treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves survival rates for patients with glioblastoma.
How similar studies have gone: While the use of dichloroacetate in treating glioblastoma is a novel approach, similar metabolic therapies have shown promise in other cancer types.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Stacpoole, Peter Wallace — University of Florida
- Study coordinator: Stacpoole, Peter Wallace
Related research
Other NIH-funded projects on the same topics.
-
Role of a brain tumor RNA in glioblastoma where a unique lncRNA may drive cancer cells
A small, focused NIH grant explores how a brain cancer–related RNA called LINC01896 might control the growth of glioblastoma stem cells and influence treatment resistance.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Enhanced delivery of neural stem cells to brain cancer with a biodegradable gel and focused ultrasound
A new treatment approach uses patient-friendly neural stem cells delivered over several months with a biodegradable gel and ultrasound to target glioblastoma.
-
STAG2 mutations and 3D genome organization in glioblastoma
A study in adults with glioblastoma examines how STAG2 gene mutations may change the 3D structure of DNA in tumor cells and drive cancer.
-
Long-lasting stem-cell delivery for glioblastoma using an injectable gel and focused ultrasound
An injectable, biodegradable gel that slowly releases tumor‑killing neural stem cells, paired with focused ultrasound to allow non-surgical re-dosing, for people with glioblastoma.
-
Understanding the STAG2 Gene in Brain Tumors
This project aims to understand how changes in a specific gene called STAG2 contribute to the growth of glioblastoma, a common type of brain tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.